← Back to Clinical Trials
RecruitingNCT06416995

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionPreeclampsia
SponsorUmraniye Education and Research Hospital
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment88
SexFEMALE
Min Age18 Years
Max Age39 Years
Start Date2023-03-03
Completion2024-11-30
Interventions
first trimester serum diagnostic test

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.

Eligibility Criteria

Inclusion Criteria: * Those who had the first-trimester screening test between 11 and 14 weeks of pregnancy and are in the low-risk group * Those with singleton pregnancy * Those who did not conceive pregnancy with assisted reproductive treatment methods * Those who do not have any pregestational diseases * Those who do not have any uterine anomalies Exclusion Criteria: * Smokers * Those who are in the high-risk group with the first trimester screening test * Those with multiple pregnancies * Those who conceive with assisted reproductive treatment methods * Those who had any disease before pregnancy * Those who have any uterine anomalies

Related Trials